迪瑞医疗：吉林证监局对公司采取责令改正措施

Core Viewpoint - The company received a decision from the Jilin Regulatory Bureau of the China Securities Regulatory Commission on February 5, 2026, regarding issues related to the recognition of revenue from foreign sales orders and internal controls [1] Group 1: Revenue Recognition Issues - The company was found to have recognized revenue from certain foreign sales orders in 2023 without the corresponding goods being actually declared for customs and subsequently returned [1] - This indicates a lack of prudence in the revenue recognition process for foreign sales orders [1] Group 2: Internal Control Deficiencies - The internal controls related to foreign sales at the company were deemed inadequate, with incomplete documentation for some foreign sales orders [1] - This highlights potential weaknesses in the company's operational processes and compliance measures [1]